+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Company Analysis: Alexion

The publisher explores Alexion’s prescription pharmaceutical performance and outlook over 2019-29.

Snapshot
  • Overview - Alexion’s rare diseases portfolio maintains its solid growth and attractive orphan drug potential.
  • Key themes - [1] Alexion might see revenue growth slow due to patient switching from Soliris to Ultomiris, which has a lower annual average cost but a longer period of exclusivity [2] Soliris revenues will be driven by uptake in neurology [3] Business development activity (Eidos, Stealth BioTherapeutics, Achillion, Portola) adds significant diversification to pipeline.
Model updates (4 November 2020)
  • Ultomiris forecast adjusted higher due to continued faster switching from Soliris
  • Soliris forecast adjusted higher due to strength in neurology indications.
Model updates (30 July 2020)
  • Ultomiris forecast adjusted higher due to faster switching from Soliris
  • Soliris forecast adjusted higher due to strength in neurology indications
  • Andexxa forecast added due to acquisition of Portola Pharmaceuticals.
Model updates (6 May 2020)
  • Ultomiris forecast adjusted higher due to faster switching from Soliris, tempered somewhat by an impact to new patient starts from COVID-19
  • Soliris forecast adjusted lower due to faster switching to Ultomiris as well as an impact to new patient starts from COVID-19.
Model updates (30 January 2020)
  • Ultomiris forecast adjusted higher due to faster switching from Soliris
  • Soliris forecast adjusted lower due to faster switching to Ultomiris.
Note: Product cover images may vary from those shown
Company Background
  • Company Overview
  • Key Metrics
  • SWOT Analysis
  • Key Drug & Company Information
  • Company Comparison
Recent Earnings Review
  • Earnings Overview
  • Pharma Insights Analysis
Company Forecast
  • Prescription Pharmaceuticals Sales Outlook
  • Branded Drug Outlook
  • Launch Profile Outlook
  • Therapy Area Outlook
  • Regional Sales Outlook
  • Lifecycle Analysis
Company Profile
  • Marketed & Pipeline Drugs
  • Recent Events & Analyst Opinions
  • Upcoming Catalysts
  • Recent Insights
Clinical Trial Overview
  • Clinical Trial Snapshot
  • Clinical Trials by Country
  • Clinical Trials by Status and Phase
  • Clinical Trials by Drug
Note: Product cover images may vary from those shown
Adroll
adroll